Chongmin Huan

Chongmin Huan, PhD, MD, serves as Assistant Professor in the Department of Cell Biology at SUNY Downstate Health Sciences University's College of Medicine, with additional appointments as Principal Investigator and Graduate Student Supervisor in the School of Graduate Studies' Molecular and Cellular Biology Program. His research focuses on autoimmune disease mechanisms, particularly systemic lupus erythematosus (lupus), utilizing genetically modified mouse models and human clinical samples to investigate B cell tolerance pathways.

Dr. Huan's primary research centers on sphingomyelin synthase 2 (SMS2) as a critical regulator of B cell tolerance in germinal centers. His seminal work demonstrates that SMS2 prevents lupus pathogenesis by activating protein kinase C delta (PKCd)-mediated apoptosis in autoreactive B cells. Current investigations examine SMS2/PKCd pathway impairment in lupus patients and its role in existing therapeutic mechanisms, with pharmacologic SMS2 activation showing promise in preclinical models.

Analysis of his publication record reveals a consistent research trajectory in sphingolipid metabolism across immunology, gastroenterology, and cardiology. His work spans lupus pathogenesis, inflammatory bowel disease, pancreatitis, and atherosclerosis, consistently identifying sphingomyelin synthases as pivotal regulators of immune tolerance and inflammatory responses through molecular and in vivo approaches.

No scientific awards were explicitly mentioned in the provided information.

Dr. Huan actively mentors graduate researchers including PhD candidate Sailee Chavan and MD/PhD candidate Shreya Desikan. His collaborative team includes Dr. Christopher Roman (Cell Biology) and Dr. Ellen Ginzler (Medicine: Rheumatology). He teaches Histology and Physiology courses for the College of Medicine, specializing in small intestine and pancreas structure and carbohydrate/water/electrolyte absorption mechanisms.

His laboratory employs advanced techniques including germinal center B cell purification protocols to investigate how sphingolipid metabolism governs immune tolerance. The research program maintains strong translational focus with ongoing efforts to develop SMS2-targeted therapies for lupus and related autoimmune conditions.